AI Article Synopsis
- SPAG1 is linked to infertility and tumor development, with its role in acute myeloid leukemia (AML) being investigated for the first time.
- High expression levels of SPAG1 in AML patients correlate with poor prognosis, but do not relate to FLT3 mutations.
- Experiments reveal that SPAG1 supports AML cell growth and survival by influencing certain signaling pathways, suggesting it could be a potential target for future treatments.
Article Abstract
Sperm-associated antigen 1 (SPAG1) is considered to be associated with infertility and tumorigenesis. However, its function in acute myeloid leukemia (AML) remains unclear. In this study, we evaluated the expression level of SPAG1 and explored its clinical prognostic value in patients with AML, as well as its biological function in AML cells. SPAG1 is widely expressed in AML patients, resulting in a poor prognosis. However, its expression was not associated with Fms-related receptor tyrosine kinase 3 (FLT3) mutations. Utilizing the RNA interference knockdown tests, we found that SPAG1 could promote the proliferation and survival of AML cells and regulate the expression of structural maintenance of chromosomes protein 3 (SMC3), activating the ERK/MAPK signaling pathway. Furthermore, we discovered that inhibiting SPAG1 impacted AML cell susceptibility to venetoclax. In conclusion, SPAG1 may serve as a potential therapeutic target in AML.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4149/neo_2022_220415N416 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Challenge of Diagnosing Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report.
Anticancer Res
January 2025
Department of Hematology/Oncology, Luminis Health Anne Arundel Medical Center, Annapolis, MD, U.S.A.
Background/aim: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive hematologic cancer which is difficult to diagnose and has a lot of overlapping features with other diseases, particularly acute myeloid leukemia (AML). BPDCN shares several immunophenotypic markers with AML, such as CD4, CD56, CD123, and HLA-DR, stating the importance of having extending panel of specific immunohistochemical (IHC) markers.
Case Report: This report details a case of CLL who presented with worsening symptoms of recurrent infections and leukocytosis.
Discovery of the salicylaldehyde-based compound DDO-02267 as a lysine-targeting covalent inhibitor of ALKBH5.
Eur J Med Chem
December 2024
State Key Laboratory of Natural Medicines, and Jiang Su Key Laboratory of Drug, Design and Optimization, China Pharmaceutical University, Nanjing, 210009, China; Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China. Electronic address:
N-methyladenosine (mA) is a crucial mRNA epigenetic modification in eukaryotes, and its methylation regulation is associated with the proliferation and metastasis of diverse tumor cells. ALKBH5 functions as a demethylase for mA and plays a role in the demethylation process, thus influencing tumor cell growth and migration. However, there are limited reports on selective small molecule inhibitors of ALKBH5.
View Article and Find Full Text PDFPost-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission.
Eur J Haematol
December 2024
Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel.
Molecular assessment of measurable residual disease (MRD) in NPM1-mutated AML patients is a powerful prognostic tool to identify the risk of relapse. There is limited data regarding MRD-guided decisions against alloSCT in elderly patients and FLT3-ITD co-mutation. We describe the outcome of NPM1-mutated AML patients in whom alloSCT was deferred based on ELN 2017 risk and MRD response.
View Article and Find Full Text PDFCombination of triciribine and p38 MAPK inhibitor PD169316 enhances the differentiation effect on myeloid leukemia cells.
PLoS One
December 2024
Department of Clinical Laboratory, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan.
Differentiation therapy with all-trans retinoic acid (ATRA) is well established for acute promyelocytic leukemia (APL). However, the narrow application and tolerance development of ATRA remain to be improved. A number of kinase inhibitors have been reported to induce cell differentiation.
View Article and Find Full Text PDFPseudo-Chediak-Higashi inclusions and Auer rods in a case of therapy-related acute monocytic leukemia.
Int J Hematol
December 2024
Hematology Laboratory, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Lyon, France.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!